These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9853694)

  • 1. An adolescent male with multiple paraphilias successfully treated with fluoxetine.
    Galli VB; Raute NJ; McConville BJ; McElroy SL
    J Child Adolesc Psychopharmacol; 1998; 8(3):195-7. PubMed ID: 9853694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment of paraphilias with a focus on antidepressants.
    Balon R
    J Sex Marital Ther; 1998; 24(4):241-54. PubMed ID: 9805285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraphilias in schizophrenia: differential diagnosis and treatment with selective serotonin reuptake inhibitors.
    Yang FW; Liang CS
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1126-7. PubMed ID: 20403404
    [No Abstract]   [Full Text] [Related]  

  • 4. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias.
    Stein DJ; Hollander E; Anthony DT; Schneier FR; Fallon BA; Liebowitz MR; Klein DF
    J Clin Psychiatry; 1992 Aug; 53(8):267-71. PubMed ID: 1386848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open trial and discontinuation study of fluoxetine in children and adolescents with obsessive-compulsive disorder.
    Semerci ZB; Unal F
    Turk J Pediatr; 2001; 43(4):323-8. PubMed ID: 11765163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obsessive compulsive disorder and depression--first results of a prospective study on 74 patients.
    Demal U; Zitterl W; Lenz G; Zapotoczky HG; Zitterl-Eglseer K
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 Jul; 20(5):801-13. PubMed ID: 8870065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study.
    Coleman E; Gratzer T; Nesvacil L; Raymond NC
    J Clin Psychiatry; 2000 Apr; 61(4):282-4. PubMed ID: 10830149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder.
    Go FS; Malley EE; Birmaher B; Rosenberg DR
    J Child Adolesc Psychopharmacol; 1998; 8(1):73-80. PubMed ID: 9639082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder.
    Ackerman DL; Greenland S; Bystritsky A
    J Clin Psychopharmacol; 1998 Jun; 18(3):185-92. PubMed ID: 9617976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: a retrospective study.
    Greenberg DM; Bradford JM; Curry S; O'Rourke A
    Bull Am Acad Psychiatry Law; 1996; 24(4):525-32. PubMed ID: 9001750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Staying Up at Night: Overlapping Bipolar and Obsessive-Compulsive Disorder Symptoms in an Adolescent with Autism Spectrum Disorder.
    Cawkwell P; Lawler A; Maneta E; Coffey BJ
    J Child Adolesc Psychopharmacol; 2016 Feb; 26(1):74-7. PubMed ID: 26881860
    [No Abstract]   [Full Text] [Related]  

  • 12. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
    López-Ibor JJ; Saiz J; Cottraux J; Note I; Viñas R; Bourgeois M; Hernández M; Gómez-Pérez JC
    Eur Neuropsychopharmacol; 1996 May; 6(2):111-8. PubMed ID: 8791036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
    Husted DS; Shapira NA; Murphy TK; Mann GD; Ward HE; Goodman WK
    J Psychiatr Res; 2007; 41(3-4):332-7. PubMed ID: 16860338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine: therapeutic and undesirable effects.
    Cookson J; Duffett R
    Hosp Med; 1998 Aug; 59(8):622-6. PubMed ID: 9829055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial.
    Kafka MP
    Ann Clin Psychiatry; 1994 Sep; 6(3):189-95. PubMed ID: 7881500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obsessive-compulsive disorder presenting with gender incongruence obsessions.
    Uvais NA; Sreeraj VS
    Asian J Psychiatr; 2017 Dec; 30():77-78. PubMed ID: 28837942
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluoxetine and compulsive sexual behavior.
    Aguirre B
    J Am Acad Child Adolesc Psychiatry; 1999 Aug; 38(8):943. PubMed ID: 10434484
    [No Abstract]   [Full Text] [Related]  

  • 20. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.
    Marazziti D; Pfanner C; Dell'Osso B; Ciapparelli A; Presta S; Corretti G; Di Nasso E; Mungai F; Dell'Osso L
    J Psychopharmacol; 2005 Jul; 19(4):392-4. PubMed ID: 15982994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.